Human Betacellulin (hBTC) #5235
Inquiry Info. # 5235
Please see our recommended alternatives.
Product Information
Formulation
Storage
Product Description
| MW (kDa) | 14 |
| Purity | >98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hBTC. All lots are greater than 98% pure. |
| Endotoxin | Less than 0.01 ng endotoxin/1 μg hBTC. |
| Activity | The bioactivity of recombinant hBTC was determined in a MCF 10A cell proliferation assay. The ED50 of each lot is between 0.6 and 1.0 ng/ml. |
| Molecular Formula | Recombinant hBTC does not have a Met at the amino terminus and has a calculated MW of 8,984. DTT-reduced and non-reduced protein migrate as 14 kDa polypeptides. The expected amino-terminal DGNST of recombinant hBTC was verified by amino acid sequencing. |
Source / Purification
Recombinant human Betacellulin (hBTC) Asp31-Tyr111 (Accession #P35070) was produced in E. coli at Cell Signaling Technology.
Background
Betacellulin (BTC), a member of the EGF family of ligands, is a widely expressed growth factor that was originally identified in conditioned medium of a mouse pancreatic beta cell line (1). BTC is synthesized as a 178 amino acid transmembrane precursor protein that is proteolytically cleaved into an 80 amino acid mature protein (1). Human BTC shares 74% amino acid sequence identity with mouse BTC (1). BTC can bind to and activate the ErbB family of receptor tyrosine kinases, EGFR/ErbB1, HER2/ErbB2, HER3/ErbB3, and HER4/ErbB4 (1,2). BTC can also bind to and activate EGFR/ErbB1 and HER4/ErbB4 homodimers (1). Ligand-receptor interactions result in the activation of the PI3K and Erk pathways (1). BTC induces the proliferation of pancreatic beta cell lines in vitro (2). Moreover, research studies have shown that BTC induces beta cell regeneration and increased insulin secretion in rodent models of diabetes (2-4).
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.